Azitra, Inc. (AZTR)
USD 0.25
(-5.17%)
USD 0.25
(-5.17%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -7.61 Million USD | 19.43% |
| 2022 | -9.45 Million USD | -2.52% |
| 2021 | -9.22 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.66 Million USD | 10.17% |
| 2024 Q1 | -2.96 Million USD | -14.78% |
| 2023 Q3 | -1.99 Million USD | -34.22% |
| 2023 Q1 | -1.55 Million USD | 42.19% |
| 2023 FY | -7.61 Million USD | 19.43% |
| 2023 Q2 | -1.48 Million USD | 4.77% |
| 2023 Q4 | -2.58 Million USD | -29.41% |
| 2022 Q1 | -2.29 Million USD | 0.0% |
| 2022 FY | -9.45 Million USD | -2.52% |
| 2022 Q4 | -2.69 Million USD | -13.82% |
| 2022 Q2 | -2.08 Million USD | 9.07% |
| 2022 Q3 | -2.37 Million USD | -13.51% |
| 2021 FY | -9.22 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.91 Million USD | 76.136% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | 19.979% |
| Armata Pharmaceuticals, Inc. | -40.89 Million USD | 81.373% |
| Actinium Pharmaceuticals, Inc. | -51.92 Million USD | 85.331% |
| Can-Fite BioPharma Ltd. | -8.19 Million USD | 7.06% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -10.989% |
| Calidi Biotherapeutics, Inc. | -28.99 Million USD | 73.729% |
| CEL-SCI Corporation | -31.47 Million USD | 75.803% |
| iBio, Inc. | -16.63 Million USD | 54.212% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 69.206% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | 62.262% |
| Matinas BioPharma Holdings, Inc. | -23.76 Million USD | 67.953% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | 45.794% |
| NovaBay Pharmaceuticals, Inc. | -5 Million USD | -52.237% |
| NanoViricides, Inc. | -8.51 Million USD | 10.565% |
| Oragenics, Inc. | -20.9 Million USD | 63.566% |
| BiomX Inc. | -27.68 Million USD | 72.489% |
| BiomX Inc. | -27.68 Million USD | 72.489% |
| Protalix BioTherapeutics, Inc. | 10.46 Million USD | 172.814% |
| Palatin Technologies, Inc. | -22.49 Million USD | 66.144% |
| Scorpius Holdings, Inc. | -42.03 Million USD | 81.88% |
| Theriva Biologics, Inc. | -21.43 Million USD | 64.461% |